Printer Friendly

BIOTECHNOLOGY INDUSTRY PLEASED WITH PRESIDENT'S SUPPORT OF TECHNOLOGY IN NEW BUDGET

 WASHINGTON, April 15 /PRNewswire/ -- Proposed spending increases in high technology research, including biotechnology, demonstrates the Clinton administration's commitment to building a strong future for the nation through applied scientific research, said the head of the nation's leading biotechnology trade associations today.
 Carl B. Feldbaum, speaking for the Industrial Biotechnology Association (IBA), and the Association of Biotechnology Companies (ABC), offered encouragement for items included in President Clinton's proposed budget package, including significant increases in funds for applied research in biotechnology and other areas of science at the National Institutes of Health, the National Science Foundation and other federal agencies.
 "The president very clearly appreciates the importance of biotechnology, and other state of the art scientific disciplines, to future economic growth in the United States," Feldbaum said. "This budget package puts real punch behind President Clinton's technology initiative.
 "President Clinton's budget shows that he recognized that sciences such as biotechnology will play a vital role in shaping the world we will live in tomorrow," commented Feldbaum.
 "It's unfortunate, however, that similar increases in funding for basic scientific research haven't been proposed," he noted. "But we would hope that the administration's support for basic research will be demonstrated in the longer term."
 Feldbaum also expressed the hope that the administration's proposed budget was not an isolated example of the president's support for biotechnology. "This level of commitment to helping biotechnology grow should be carried through in other areas of administration policy, most notably in health care reform. All of the good the president is trying to achieve through his proposed increases in applied research funding can be undone by regressive measures such as placing controls on the prices of new innovative drugs."
 The Association of Biotechnology Companies is a not-for-profit trade association with more than 350 members from 27 countries, including biotechnology companies, state and academic biotechnology research centers, non-profit and government-affiliated entities and other organizations interested in biotechnology.
 The Industrial Biotechnology Association represents more than 150 companies that are responsible for more than 85 percent of the sales, revenues and research and development expenditures in the biotechnology industry.
 The Biotechnology Industry Organization is being created out of an agreement-in-principle by ABC and IBA to merge into a single organization. Carl Feldbaum is directing the merger activities of the two groups until the planned merger date of July 1, when he will become president of the new organization.
 -0- 4/15/93
 /CONTACT: Eric Christensen of the Industrial Biotechnology Association, 202-857-0244/


CO: Industrial Biotechnology Association ST: District of Columbia IN: MTC SU: EXE

IH-KD -- DC999 -- 6124 04/15/93 10:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 15, 1993
Words:429
Previous Article:BIO MERGER APPROVED BY ABC MEMBERSHIP; 'NEW ERA IN U.S. BIOTECHNOLOGY INDUSTRY HAS BEGUN'
Next Article:COLUMBIA HOSPITAL CORPORATION REPORTS CONTINUED EXPANSION IN FIRST QUARTER PATIENT VOLUMES
Topics:


Related Articles
BIO MERGER APPROVED BY ABC MEMBERSHIP; 'NEW ERA IN U.S. BIOTECHNOLOGY INDUSTRY HAS BEGUN'
EPITOPE FORMS GRAPE PLANT BIOTECHNOLOGY SUBSIDIARY
INCREASED EMPLOYMENT AT MASSACHUSETTS BIOTECHNOLOGY COMPANIES EXPECTED IN 1996
Washington Biotechnology & Medical Technology Online - News Resources, New Look, New Ownership
Genzyme Comments on Federal Budget Agreement.
MASS Opportunities Annual Biotech Investment Conference October 27 & 28 Celebrates Fifth Year as New England's Largest Industry Investor Forum; --...
Local Biotech Industry Highlights Negative Impact of Drug Reimportation On Massachusetts Economy and Patient Care.
Governor Pataki Announces New Programs Supporting Biotech Growth in 2004 State of the State Address.
Norak Biosciences Licences Transfluor Technology to DCB.
Norak Biosciences Licenses Transfluor(R) Technology to DCB; Development Center for Biotechnology in Taiwan will use Transfluor(R) for GPCR drug...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters